Scientific Resources
Our next-generation diagnostic assays have generated novel insights across a broad range of clinical applications.
Access our presentations, publications, and more to see how we’re unlocking the full potential of precision genomics.
Found 32 Results
Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.
March 9, 2023 | Poster
Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
November 15, 2022 | Presentation
Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-cell Lymphoma
April 29, 2022 | Poster
Inferring gene expression from cell-free DNA fragmentation profiles
April 1, 2022 | Manuscript
Nature Biopharma Dealmakers: Closing the gap on minimal residual disease detection in cancer
March 29, 2022 | Article
Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing
December 13, 2021 | Abstract